{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:48Z","timestamp":1784557008357,"version":"3.55.0"},"reference-count":11,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,6,8]]},"abstract":"Summary<\/jats:title>\n In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs.<\/jats:p>\n \n Learning points<\/jats:title>\n \n \n \n Prolactinoma coinciding with psychosis can represent a therapeutic challenge.<\/jats:p>\n <\/jats:list-item>\n \n In contrast to many other antipsychotic drugs, aripiprazole is associated with a decrease in prolactin levels.<\/jats:p>\n <\/jats:list-item>\n \n Aripiprazole can be a valuable pharmaceutical tool to treat both prolactinoma and psychosis.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/edm-16-0028","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T12:01:32Z","timestamp":1465300892000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":5,"title":["Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole"],"prefix":"10.1530","volume":"2016","author":[{"given":"Ilse C A","family":"Bakker","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Section of Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris D","family":"Schubart","sequence":"additional","affiliation":[{"name":"2Department of Psychiatry, Tergooi Hospital, Hilversum, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre M J","family":"Zelissen","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section of Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"key20160609145007144_bib1","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"key20160609145007144_bib2","doi-asserted-by":"crossref","first-page":"140020","DOI":"10.1530\/EDM-14-0020","article-title":"Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma","volume":"2014","author":"Prague","year":"2014","journal-title":"Endocrinology, Diabetes & Metabolism Case Reports"},{"key":"key20160609145007144_bib3","doi-asserted-by":"crossref","unstructured":"KonopelskaSQuinklerMStrasburgerCJVentzM 2008 Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia \u2013 a case report with a review of the literature. Journal of Clinical Psychopharmacology 28 120\u2013122. (doi:10.1097\/jcp.0b013e3181603f8f)","DOI":"10.1097\/jcp.0b013e3181603f8f"},{"key":"key20160609145007144_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(96)00920-X","article-title":"Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.","volume":"321","author":"Inoue","year":"1997","journal-title":"European Journal of Pharmacology"},{"issue":"e70179","key":"key20160609145007144_bib5","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinaemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PLoS ONE"},{"key":"key20160609145007144_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III \u2013 the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"key20160609145007144_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"key20160609145007144_bib8","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"key20160609145007144_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-2008-1076721","article-title":"Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis","volume":"41","author":"Sheldrick","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"key20160609145007144_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.pra.0000265771.47153.a0","article-title":"Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma","volume":"13","author":"Freeman","year":"2007","journal-title":"Journal of Psychiatric Practice"},{"issue":"EDM150100","key":"key20160609145007144_bib11","article-title":"Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania","volume":"2015","author":"Burback","year":"2015","journal-title":"Endocrinology, Diabetes & Metabolism Case Reports"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2016\/1\/EDM16-0028.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2016\/1\/EDM16-0028.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:18Z","timestamp":1784555178000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":11,"URL":"https:\/\/doi.org\/10.1530\/edm-16-0028","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]}}}